- Status:
- Red
- Decision Date:
- March 2024
Comments
RED: NICE TA952 Talazoparib
for treating HER2- negative advanced breast cancer with germline BRCA mutations. NHSE commissioned. (Decision date - March 2024)
Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again